8 research outputs found
A novel high-content phenotypic screen to identify inhibitors of mitochondrial DNA maintenance in trypanosomes
Kinetoplastid parasites cause diverse neglected diseases in humans and livestock, with an urgent need for new treatments. The survival of kinetoplastids depends on their uniquely structured mitochondrial genome (kDNA), the eponymous kinetoplast. Here, we report the development of a high-content screen for pharmacologically induced kDNA loss, based on specific staining of parasites and automated image analysis. As proof of concept, we screened a diverse set of ∼14,000 small molecules and exemplify a validated hit as a novel kDNA-targeting compound
Colon cancer-derived myofibroblasts increase endothelial cell migration by glucocorticoid-sensitive secretion of a pro-migratory factor
AbstractAngiogenesis is important in cancer progression and can be influenced by tumor-associated myofibroblasts. We addressed the hypothesis that glucocorticoids indirectly affect angiogenesis by altering the release of pro-angiogenic factors from colon cancer-derived myofibroblasts.Our study shows that glucocorticoids reduced prostanoids, urokinase-type plasminogen activator (uPA) and angiopoietin-like protein-2 (ANGPTL2) levels, but increased angiogenin (ANG) in supernatant from human CT5.3hTERT colon cancer-derived myofibroblasts. Conditioned medium from solvent- (CMS) and dexamethasone (Dex)-treated (CMD) myofibroblasts increased human umbilical vein endothelial cell (HUVEC) proliferation, but did not affect expression of pro-angiogenic factors or tube-like structure formation (by HUVECs or human aortic ECs). In a HUVEC scratch assay CMS-induced acceleration of wound healing was blunted by CMD treatment. Moreover, CMS-induced neovessel growth in mouse aortic rings ex vivo was also blunted using CMD. The latter effect could be ascribed to both Dex-driven reduction of secreted factors and potential residual Dex present in CMD (indicated using a dexamethasone-spiked CMS control). A similar control in the scratch assay, however, revealed that altered levels of factors in the CMD, and not potential residual Dex, were responsible for decreased wound closure.In conclusion, our results suggest that glucocorticoids indirectly alter endothelial cell function during tumor development in vivo
Colon cancer-derived myofibroblasts increase endothelial cell migration by glucocorticoid-sensitive secretion of a pro-migratory factor
status: publishe
Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
Background Metastatic breast cancer is a leading cause of cancer-related death in women worldwide. Infusion of natural killer (NK) cells is an emerging immunotherapy for such malignant tumors, although elimination of the immunosuppressive tumor environment is required to improve its efficacy. The effects of this “metastatic” tumor environment on NK cells, however, remain largely unknown. Previous studies, including our own, have demonstrated that metastasis-associated macrophages (MAMs) are one of the most abundant immune cell types in the metastatic tumor niche in mouse models of metastatic breast cancer. We thus investigated the effects of MAMs on antitumor functions of NK cells in the metastatic tumor microenvironment.Methods MAMs were isolated from the tumor-bearing lung of C57BL/6 mice intravenously injected with E0771-LG mouse mammary tumor cells. The effects of MAMs on NK cell cytotoxicity towards E0771-LG cells were evaluated in vitro by real-time fluorescence microscopy. The effects of MAM depletion on NK cell activation, maturation, and accumulation in the metastatic lung were evaluated by flow cytometry (CD69, CD11b, CD27) and in situ hybridization (Ncr1) using colony-stimulating factor 1 (CSF-1) receptor conditional knockout (Csf1r-cKO) mice. Finally, metastatic tumor loads in the chest region of mice were determined by bioluminescence imaging in order to evaluate the effect of MAM depletion on therapeutic efficacy of endogenous and adoptively transferred NK cells in suppressing metastatic tumor growth.Results MAMs isolated from the metastatic lung suppressed NK cell-induced tumor cell apoptosis in vitro via membrane-bound transforming growth factor β (TGF-β) dependent mechanisms. In the tumor-challenged mice, depletion of MAMs increased the percentage of activated (CD69+) and mature (CD11b+CD27–) NK cells and the number of Ncr1+ NK cells as well as NK cell-mediated tumor rejection in the metastatic site. Moreover, MAM depletion or TGF-β receptor antagonist treatment significantly enhanced the therapeutic efficacy of NK cell infusion in suppressing early metastatic tumor outgrowth.Conclusion This study demonstrates that MAMs are a main negative regulator of NK cell function within the metastatic tumor niche, and MAM targeting is an attractive strategy to improve NK cell-based immunotherapy for metastatic breast cancer
Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1S⃞
The dual-specificity protein tyrosine phosphatases (PTPs) play integral roles in the
regulation of cell signaling. There is a need for new tools to study these
phosphatases, and the identification of inhibitors potentially affords not only new
means for their study, but also possible therapeutics for the treatment of diseases
caused by their dysregulation. However, the identification of selective inhibitors of
the protein phosphatases has proven somewhat difficult. PTP localized to
mitochondrion 1 (PTPMT1) is a recently discovered dual-specificity phosphatase that
has been implicated in the regulation of insulin secretion. Screening of a
commercially available small-molecule library yielded alexidine dihydrochloride, a
dibiguanide compound, as an effective and selective inhibitor of PTPMT1 with an in
vitro concentration that inhibits response by 50% of 1.08 μM. A related
dibiguanide analog, chlorhexidine dihydrochloride, also significantly inhibited
PTPMT1, albeit with lower potency, while a monobiguanide analog showed very weak
inhibition. Treatment of isolated rat pancreatic islets with alexidine
dihydrochloride resulted in a dose-dependent increase in insulin secretion, whereas
treatment of a pancreatic β-cell line with the drug affected the
phosphorylation of mitochondrial proteins in a manner similar to genetic inhibition
of PTPMT1. Furthermore, knockdown of PTPMT1 in rat islets rendered them insensitive
to alexidine dihydrochloride treatment, providing evidence for mechanism-based
activity of the inhibitor. Taken together, these studies establish alexidine
dihydrochloride as an effective inhibitor of PTPMT1, both in vitro and in cells, and
support the notion that PTPMT1 could serve as a pharmacological target in the
treatment of type II diabetes